CTLA4 and melanoma: Consequently, reducing S1P levels by silencing SPHK1 improves the efficacy of anti-CTLA-4 and anti-PD-1 immunotherapy, leading to significant tumor suppression and overall improved survival in mouse melanoma, breast, and colon tumor models [18].